App-Quantinova.ai

Impact of Cystatin C and Microalbuminuria on Cognitive Impairment in the Population of Community-dwelling Japanese

Hisashi Adachi - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Cognitive dysfunction

N/A

The Preventive Effect of Angiotensin-converting Enzyme Inhibitor on Renal Function in the Late Phase After Percutaneous Coronary Intervention in Patients With Statin

Takuro Takumi - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Chronic kidney disease

Angiotensin II

Cystatin C is a Strong Predictor of Short-term Functional Outcome After Ischemic Stroke in Patients With Chronic Kidney Disease

Chi Kyung Kim - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Chronic kidney disease

N/A

A Cluster of Proteins Implicated in Kidney Disease Are Increased in HDL of Hemodialysis Subjects

Ian de Boer - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Microvascular complications of diabetes 1

N/A

Cystatin C Predicts Diastolic Dysfunction in Children with Chronic Kidney Disease, Independent of Kidney Function

Kelly C. McDermott - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

Omnipaque 350

Cystatin C Based Estimated Glomerular Filtration Rate is a Feasible Parameter for Incident Stroke in Patients with Atrial Fibrillation

Satoshi Nishiyama - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Cardiac valvular dysplasia X-linked

N/A

Remote Ischemic Preconditioning Attenuates Renal Ischemia-Reperfusion Injury in a Model of Thoracoabdominal Aortic Aneurysm Open Repair

Dimitrios Athanasiadis - American Heart Association (AHA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Renal ischemia reperfusion injury

N/A

Neuronal Voltage-Dependent Calcium Channel 2.1 RNA Increased in Animal Models With Contrast-Induced Nephropathy

Luyu Yao - American Heart Association (AHA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Contrast-induced Acute Kidney Injury

Prostaglandin

Protein Profiling for Survival Outcome Prediction in Out-of-Hospital Cardiac Arrest Patients

Min-Shan Tsai - American Heart Association (AHA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Cardiac arrest

Interleukin-10

Intraventricular Administration of Cystatin C Attenuates White Matter Injury In Rat Chronic Ischemia

Atsushi Nagai - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

White matter injury

Cysteine Hydrochloride

Cystatin C is Associated with Early Functional Outcome in Acute Stroke Patients

Seung-Hoon Lee - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Ischemic stroke

Fibrinogen (IV)

Cystatin C, a Novel Indicator of Kidney Function, Reflects Severity of Cerebral Small Vessel Disease

Seung-Hoon Lee - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Cerebral small vessel disease

Cysteine Hydrochloride

Glomerular Filtration Rate Estimated by Cystatin C- versus Creatinine-Based Equations for Predicting Cardiovascular Mortality in Patients Hospitalized for Worsening Heart Failure Without Advanced Renal Impairment

Junnichi Ishii - American Heart Association (AHA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Congestive heart failure

N/A

Cystatin C and Body Surface Area Are Major Determinants of the Ratio of N-Terminal Pro-Brain Natriuretic Peptide to Brain Natriuretic Peptide Levels in Pediatric Patients

Satoshi Masutani - American Heart Association (AHA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Renal insufficiency

N/A

Association Between Serum Cystatin C Level and Cardiometabolic Risk Factors Among Japanese Junior High School Students

Atsushi Izawa - American Heart Association (AHA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metabolic syndrome

N/A

Significant Association of Serum Cystatin C with Coronary Calcification Evaluated by Tomographic Coronary Calcium Scoring

Takashi Miki - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Coronary Artery Disease

N/A

Genetic Polymorphism and Relationship to Cystatin C Concentrations and Outcome - Results From the Platelet Inhibition and Patient Outcomes Study

Lars Wallentin - American Heart Association (AHA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute Coronary Syndromes

N/A

Cystatin C is Superior to Creatinine for Predicting Sudden Cardiac Arrest in Ischemic Cardiomyopathy

Grzegorz Pietrasik - American Heart Association (AHA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

Angiotensin II

Cystatin C is Superior to Creatinine for Prediction of Adverse Events in Heart Failure Patients Undergoing LVAD Implant

A. Pinsino - International Society for Heart & Lung Transplantation (ISHLT) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Right ventricular failure

N/A

Utility of Serum Cystatin C in Early Kidney Dysfunction in Prediabetics

JULIA I.F. BRANDA - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Filters

169 Abstracts